Oct 22, 2021 09:04 PM (GMT+8) · EqualOcean
Cailian, October 22 (Xinhua) -- boten Co., Ltd. announced that the company plans to establish Chongqing Changsheng Shenghe pharmaceutical private equity investment fund partnership (limited partnership) (tentative name, finally subject to the name approved and registered by the industry and commerce, "MAH fund" or "fund") jointly with point Petrochemical medicine, guangyangwan fund and Xintian investment, focusing on investing in key intermediates in the field of highly difficult and complex preparations Mah company with production cost advantages or technical barriers in API, preparation and other links. As one of the limited partners of the fund, the company plans to subscribe 122.5 million yuan, accounting for 35% of the total subscribed capital of the fund.

This text is a result of machine translation.